-+ 0.00%
-+ 0.00%
-+ 0.00%

Spruce Biosciences Q3 2026 net loss more than doubles to $24.01 million

PUBT·11/09/2026 13:02:24
Listen to the news
Spruce Biosciences Q3 2026 net loss more than doubles to $24.01 million
  • Spruce Biosciences’ third-quarter 2026 net loss more than doubled year over year to $24.01 million.
  • R&D expenses more than tripled to $18.13 million, primarily due to higher TA-ERT manufacturing and clinical development spending.
  • Cash totaled $87.7 million at September 30, with planned operations and debt obligations funded into the second half of 2027.
  • TA-ERT’s BLA submission remains targeted for December 2026, alongside initiation of the TrAnsform confirmatory study.
  • The CRHX-101 program moved into Adrenyx Biosciences, with distribution of its shares to stockholders expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109551994) on November 09, 2026, and is solely responsible for the information contained therein.